Gujarat Themis Biosyn posts Q1 FY24 PAT at Rs. 17.72 Cr
Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023
Gujarat Themis Biosyn has reported total income of Rs. 50.66 crores during the period ended June 30, 2023
The first such initiative under the MoU will involve establishing a Centre of Excellence for Renal Sciences at the Tomo Riba Institute of Health & Medical Sciences (TRIHMS)
Natural Capsules Ltd. has reported total income of Rs. 37.87 crores during the period ended June 30, 2023
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
US FDA approval is in line with de-risking strategy for additional API site to service our global customer base
The inspection was conducted at its Goa, Vema manufacturing facility
The inspection closed with zero observations and a classification of No Action Indicated
The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023
Subscribe To Our Newsletter & Stay Updated